NACDS utilizes Rapid Response program to dispute inaccurate assertions on drug importation
ALEXANDRIA, Va. The National Association of Chain Drug Stores implemented its Rapid Response Program, following a recent editorial on drug importation.
NACDS president and CEO Steve Anderson penned a response to the editor to the Delaware County Daily Times (Delaware County, Pa.) after an editorial ran on Aug. 19, which cited NACDS and asserted that chain drug stores should not be concerned about where prescription medications come from so long as they are less expensive for consumers to purchase.
“Pharmacies are convenient, accessible healthcare providers. Your neighborhood pharmacist counsels patients in obtaining the most cost effective and appropriate medications and therapies to improve their health outcomes,” Anderson wrote to the paper. “However, we do not believe that consumer safety should be compromised to achieve lower costs. Safety cannot be ensured in any system that allows for the personal importation of prescription medications. In addition, individuals who obtain prescription medications through a personal importation scheme do not have a licensed pharmacist available to consult with them about using the medications safely and effectively.”
The NACDS Rapid Response Program was created to address inaccurate or inappropriate portrayals of pharmacy, or call attention to an issue that impacts the pharmacy industry.
FDA approves Ranbaxy’s generic peptic ulcer treatment
PRINCETON, N.J. The Food and Drug Administration has given an India-based drug maker final approval to market a generic drug for treating peptic ulcer.
Ranbaxy Pharmaceuticals, a U.S. subsidiary of Ranbaxy Labs, announced Monday the approval of glycopyrrolate tablets in the 1-mg and 2-mg strengths. The drug is a generic version of Sciele Pharma’s Robinul and Robinul Forte tablets, respectively.
“We are pleased to receive this final approval for glycopyrrolate tablets,” Ranbaxy Pharmaceuticals VP sales and distribution Jim Meehan said in a statement.
Meehan said the drug would be launched between October and December. Glycopyrrolate tablets had sales of $26 million during the 12-month period ending in June, according to IMS Health data.
Supervalu EVP joins NACDS board of directors
ALEXANDRIA, Va. An organization catering to the retail pharmacy industry has elected a new member to its board.
The National Association of Chain Drug Stores announced that Duncan Mac Naughton, EVP merchandising and marketing for Supervalu, was elected to the board of directors, effective Aug. 14. Mac Naughton will fill the position vacated by Kevin Tripp, who recently retired as Supervalu’s EVP of its retail Midwest division.
Mac Naughton will serve the remainder of the 2009-2010 term until April 2010, when the annual board of directors elections are held at the NACDS Annual Meeting.
Mac Naughton has a career of service within the supermarket industry. He has served on SUPERVALU’s executive team since joining the company in 2006 upon its acquisition of Albertsons, where Mac Naughton had served as executive vice president of merchandising. Prior to Albertsons, he served in key leadership roles at H-E-B and Kraft Foods.
“We are pleased to welcome Duncan to the NACDS Board of Directors,” said NACDS president and CEO Steve Anderson. “NACDS’ diverse membership is well-represented by the NACDS Board of Directors. Duncan brings leadership and expertise on behalf of the supermarket segment, and we look forward to working together to advance pharmacy as the face of neighborhood healthcare and to add value to NACDS’ engagement in front-end activities.”